Pinnacle Associates LTD Biogen Inc. Transaction History

Pinnacle Associates LTD

$6.3 Billion
Q3 2024

A detailed history of Pinnacle Associates LTD transactions in Biogen Inc. stock. As of the latest transaction made, Pinnacle Associates LTD holds 4,557 shares of BIIB stock, worth $668,922. This represents 0.01% of its overall portfolio holdings.

Number of Shares

4,557

Previous 4,630 1.58%

Holding current value

$668,922

Previous $1.07 Million 17.71%

% of portfolio

0.01%

Previous 0.02%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 25, 2024	SELL	$189.07 - $236.8 $13,802 - $17,286	-73 Reduced 1.58%	4,557 $883,000
Q2 2024 Jul 30, 2024	SELL	$190.52 - $236.72 $24,958 - $31,010	-131 Reduced 2.75%	4,630 $1.07 Million
Q1 2024 Apr 26, 2024	BUY	$212.02 - $267.71 $43,252 - $54,612	204 Added 4.48%	4,761 $1.03 Million
Q4 2023 Jan 19, 2024	BUY	$222.59 - $267.94 $3,561 - $4,287	16 Added 0.35%	4,557 $1.18 Million
Q3 2023 Oct 23, 2023	BUY	$253.3 - $285.89 $28,369 - $32,019	112 Added 2.53%	4,541 $1.17 Million
Q2 2023 Jul 26, 2023	BUY	$275.25 - $318.06 $2,752 - $3,180	10 Added 0.23%	4,429 $1.26 Million
Q1 2023 May 04, 2023	SELL	$256.56 - $292.34 $48,233 - $54,959	-188 Reduced 4.08%	4,419 $1.23 Million
Q4 2022 Jan 31, 2023	BUY	$252.44 - $306.72 $11,864 - $14,415	47 Added 1.03%	4,607 $1.28 Million
Q4 2022 Jan 25, 2023	SELL	$252.44 - $306.72 $10,602 - $12,882	-42 Reduced 0.91%	4,560 $0
Q3 2022 Oct 31, 2022	BUY	$194.69 - $268.46 $13,044 - $17,986	67 Added 1.48%	4,602 $1.23 Million
Q2 2022 Aug 02, 2022	BUY	$187.54 - $223.02 $4,688 - $5,575	25 Added 0.55%	4,535 $925,000
Q1 2022 May 05, 2022	SELL	$193.77 - $244.14 $188,344 - $237,304	-972 Reduced 17.73%	4,510 $950,000
Q4 2021 Feb 02, 2022	BUY	$223.92 - $287.77 $17,017 - $21,870	76 Added 1.41%	5,482 $1.32 Million
Q3 2021 Oct 19, 2021	BUY	$282.99 - $369.05 $216,204 - $281,954	764 Added 16.46%	5,406 $1.53 Million
Q2 2021 Aug 02, 2021	SELL	$259.0 - $414.71 $231,028 - $369,921	-892 Reduced 16.12%	4,642 $1.61 Million
Q1 2021 May 12, 2021	SELL	$242.95 - $284.63 $76,529 - $89,658	-315 Reduced 5.39%	5,534 $1.55 Million
Q4 2020 Jan 26, 2021	SELL	$236.26 - $355.63 $141,047 - $212,311	-597 Reduced 9.26%	5,849 $1.43 Million
Q3 2020 Oct 23, 2020	BUY	$264.77 - $305.71 $1,853 - $2,139	7 Added 0.11%	6,446 $1.83 Million
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $76,046 - $100,709	294 Added 4.78%	6,439 $1.72 Million
Q1 2020 May 13, 2020	BUY	$268.85 - $341.04 $45,973 - $58,317	171 Added 2.86%	6,145 $1.94 Million
Q4 2019 Feb 03, 2020	SELL	$220.06 - $304.07 $626,070 - $865,079	-2,845 Reduced 32.26%	5,974 $1.77 Million
Q3 2019 Nov 08, 2019	BUY	$217.44 - $243.88 $30,876 - $34,630	142 Added 1.64%	8,819 $2.05 Million
Q2 2019 Aug 05, 2019	SELL	$219.29 - $241.72 $896,676 - $988,393	-4,089 Reduced 32.03%	8,677 $2.03 Million
Q1 2019 May 10, 2019	SELL	$216.71 - $338.96 $41,608 - $65,080	-192 Reduced 1.48%	12,766 $3.02 Million
Q4 2018 Feb 05, 2019	SELL	$278.5 - $352.75 $280,171 - $354,866	-1,006 Reduced 7.2%	12,958 $3.9 Million
Q3 2018 Nov 13, 2018	SELL	$293.51 - $383.83 $277,073 - $362,335	-944 Reduced 6.33%	13,964 $4.93 Million
Q2 2018 Aug 08, 2018	SELL	$257.52 - $306.91 $56,396 - $67,213	-219 Reduced 1.45%	14,908 $4.33 Million
Q1 2018 May 11, 2018	BUY	$260.13 - $367.91 $464,071 - $656,351	1,784 Added 13.37%	15,127 $4.14 Million
Q4 2017 Feb 12, 2018	BUY	$307.64 - $344.58 $1.26 Million - $1.41 Million	4,091 Added 44.22%	13,343 $4.25 Million
Q3 2017 Nov 13, 2017	SELL	$281.15 - $329.69 $17,712 - $20,770	-63 Reduced 0.68%	9,252 $2.9 Million
Q2 2017 Aug 09, 2017	BUY	N/A	9,315	9,315 $2.53 Million

Others Institutions Holding BIIB

# of Institutions

1,038

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.

Account

Pinnacle Associates LTD Biogen Inc. Transaction History